CELC Celcuity | $39.91
+1.9% | 7/28/2025 | Andrew Berens | Boost Price Target | Outperform -> Outperform | $28.00 -> $60.00 | View details for Leerink Partners rating of Celcuity (NASDAQ:CELC) on 7/28/2025 |
ABVX Abivax | $71.94
+0.2% | 7/23/2025 | Thomas Smith | Set Price Target | Outperform -> Outperform | $74.00 | View details for Leerink Partners rating of Abivax (NASDAQ:ABVX) on 7/23/2025 |
REPL Replimune Group | $7.60
+8.1% | 7/22/2025 | Jonathan Chang | Reiterated Rating | Outperform -> Market Perform | $21.00 -> $3.00 | View details for Leerink Partners rating of Replimune Group (NASDAQ:REPL) on 7/22/2025 |
SRPT Sarepta Therapeutics | $15.91
-3.1% | 7/21/2025 | - | Reiterated Rating | Outperform -> Market Perform | | View details for Leerink Partners rating of Sarepta Therapeutics (NASDAQ:SRPT) on 7/21/2025 |
ELV Elevance Health | $274.10
-3.2% | 7/18/2025 | Whit Mayo | Reiterated Rating | Outperform -> Market Perform | $510.00 -> $310.00 | View details for Leerink Partners rating of Elevance Health (NYSE:ELV) on 7/18/2025 |
IDXX IDEXX Laboratories | $535.54
+0.2% | 7/17/2025 | Daniel Clark | Boost Price Target | Outperform -> Outperform | $580.00 -> $600.00 | View details for Leerink Partners rating of IDEXX Laboratories (NASDAQ:IDXX) on 7/17/2025 |
ZTS Zoetis | $147.40
+1.1% | 7/17/2025 | Daniel Clark | Downgrade | Outperform -> Market Perform | $180.00 -> $155.00 | View details for Leerink Partners rating of Zoetis (NYSE:ZTS) on 7/17/2025 |
ELAN Elanco Animal Health | $13.80
+0.9% | 7/17/2025 | Daniel Clark | Upgrade | Market Perform -> Outperform | $18.00 | View details for Leerink Partners rating of Elanco Animal Health (NYSE:ELAN) on 7/17/2025 |
HSIC Henry Schein | $67.98
+0.5% | 7/14/2025 | Michael Cherny | Set Price Target | | $75.00 | View details for Leerink Partners rating of Henry Schein (NASDAQ:HSIC) on 7/14/2025 |
PGNY Progyny | $22.49
-4.3% | 7/8/2025 | Michael Cherny | Upgrade | Market Perform -> Outperform | $28.00 | View details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 7/8/2025 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
KALV KalVista Pharmaceuticals | $13.21
-3.1% | 7/7/2025 | Joseph Schwartz | Boost Price Target | Outperform -> Outperform | $18.00 -> $20.00 | View details for Leerink Partners rating of KalVista Pharmaceuticals (NASDAQ:KALV) on 7/7/2025 |
COGT Cogent Biosciences | $11.40
-0.2% | 7/7/2025 | Andrew Berens | Boost Price Target | Outperform -> Outperform | $16.00 -> $18.00 | View details for Leerink Partners rating of Cogent Biosciences (NASDAQ:COGT) on 7/7/2025 |
ABCL AbCellera Biologics | $4.24
-5.1% | 7/7/2025 | Faisal Khurshid | Initiated Coverage | Outperform | $5.00 | View details for Leerink Partners rating of AbCellera Biologics (NASDAQ:ABCL) on 7/7/2025 |
RYTM Rhythm Pharmaceuticals | $88.30
+3.6% | 7/7/2025 | Faisal Khurshid | Initiated Coverage | Outperform -> Outperform | $88.00 | View details for Leerink Partners rating of Rhythm Pharmaceuticals (NASDAQ:RYTM) on 7/7/2025 |
PFE Pfizer | $23.49
+0.9% | 4/30/2025 | - | Lower Price Target | Market Perform | $28.00 -> $26.00 | View details for Leerink Partners rating of Pfizer (NYSE:PFE) on 4/30/2025 |
ZLAB Zai Lab | $36.82
-2.6% | 6/30/2025 | Jonathan Chang | Set Price Target | Outperform -> Outperform | $73.00 -> $75.00 | View details for Leerink Partners rating of Zai Lab (NASDAQ:ZLAB) on 6/30/2025 |
NUVL Nuvalent | $77.76
-0.8% | 6/24/2025 | Andrew Berens | Boost Price Target | Outperform -> Outperform | $125.00 -> $140.00 | View details for Leerink Partners rating of Nuvalent (NASDAQ:NUVL) on 6/24/2025 |
ABT Abbott Laboratories | $127.32
+0.9% | 6/16/2025 | - | Initiated Coverage | Market Perform | $143.00 | View details for Leerink Partners rating of Abbott Laboratories (NYSE:ABT) on 6/16/2025 |
MDT Medtronic | $89.31
-1.0% | 6/16/2025 | Mike Kratky | Initiated Coverage | Outperform | $110.00 | View details for Leerink Partners rating of Medtronic (NYSE:MDT) on 6/16/2025 |
BSX Boston Scientific | $105.40
+0.5% | 6/16/2025 | Mike Kratky | Initiated Coverage | Outperform | $118.00 | View details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 6/16/2025 |
IDXX IDEXX Laboratories | $535.54
+0.2% | 6/11/2025 | Daniel Clark | Boost Price Target | Outperform -> Outperform | $515.00 -> $580.00 | View details for Leerink Partners rating of IDEXX Laboratories (NASDAQ:IDXX) on 6/11/2025 |
SMMT Summit Therapeutics | $27.07
+2.7% | 6/11/2025 | Daina Graybosch | Initiated Coverage | Underperform | $12.00 | View details for Leerink Partners rating of Summit Therapeutics (NASDAQ:SMMT) on 6/11/2025 |
INSM Insmed | $108.69
+1.3% | 6/10/2025 | Joseph Schwartz | Boost Price Target | Outperform -> Outperform | $100.00 -> $115.00 | View details for Leerink Partners rating of Insmed (NASDAQ:INSM) on 6/10/2025 |
DHR Danaher | $197.08
0.0% | 4/17/2025 | - | Lower Price Target | Outperform | $260.00 -> $225.00 | View details for Leerink Partners rating of Danaher (NYSE:DHR) on 4/17/2025 |
DHR Danaher | $197.08
0.0% | 4/23/2025 | - | Boost Price Target | Outperform | $225.00 -> $230.00 | View details for Leerink Partners rating of Danaher (NYSE:DHR) on 4/23/2025 |
BNTX BioNTech | $107.34
-0.1% | 6/2/2025 | Daina Graybosch | Set Price Target | | $112.00 | View details for Leerink Partners rating of BioNTech (NASDAQ:BNTX) on 6/2/2025 |
ARVN Arvinas | $7.42
-0.3% | 6/2/2025 | Andrew Berens | Reiterated Rating | Outperform -> Market Perform | $10.00 -> $9.00 | View details for Leerink Partners rating of Arvinas (NASDAQ:ARVN) on 6/2/2025 |
A Agilent Technologies | $113.51
-1.1% | 5/30/2025 | - | Boost Price Target | Buy | $135.00 | View details for Leerink Partners rating of Agilent Technologies (NYSE:A) on 5/30/2025 |
RCKT Rocket Pharmaceuticals | $2.99
-2.0% | 5/28/2025 | Mani Foroohar | Reiterated Rating | Outperform -> Market Perform | $37.00 -> $8.00 | View details for Leerink Partners rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 5/28/2025 |
FULC Fulcrum Therapeutics | $6.83
+1.5% | 5/23/2025 | Joseph Schwartz | Upgrade | Market Perform -> Outperform | $4.00 -> $12.00 | View details for Leerink Partners rating of Fulcrum Therapeutics (NASDAQ:FULC) on 5/23/2025 |
ITOS iTeos Therapeutics | $10.09
-0.5% | 5/14/2025 | Daina Graybosch | Reiterated Rating | Outperform -> Market Perform | $47.00 -> $9.00 | View details for Leerink Partners rating of iTeos Therapeutics (NASDAQ:ITOS) on 5/14/2025 |
JNJ Johnson & Johnson | $167.33
+1.6% | 5/13/2025 | David Risinger | Downgrade | Outperform -> Market Perform | $169.00 -> $153.00 | View details for Leerink Partners rating of Johnson & Johnson (NYSE:JNJ) on 5/13/2025 |
HALO Halozyme Therapeutics | $59.02
-1.6% | 5/13/2025 | - | Downgrade | Market Perform -> Underperform | $47.00 | View details for Leerink Partners rating of Halozyme Therapeutics (NASDAQ:HALO) on 5/13/2025 |
AMLX Amylyx Pharmaceuticals | $7.72
-3.9% | 5/7/2025 | Marc Goodman | Upgrade | Market Perform -> Outperform | $4.00 -> $10.00 | View details for Leerink Partners rating of Amylyx Pharmaceuticals (NASDAQ:AMLX) on 5/7/2025 |
VRTX Vertex Pharmaceuticals | $462.13
+1.2% | 5/6/2025 | David Risinger | Reiterated Rating | Outperform -> Market Perform | $550.00 -> $503.00 | View details for Leerink Partners rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 5/6/2025 |
QTRX Quanterix | $5.86
-1.3% | 4/30/2025 | Puneet Souda | Reiterated Rating | Outperform -> Market Perform | $12.00 -> $8.00 | View details for Leerink Partners rating of Quanterix (NASDAQ:QTRX) on 4/30/2025 |
NEO NeoGenomics | $5.16
+6.6% | 4/30/2025 | Puneet Souda | Downgrade | Outperform -> Market Perform | $25.00 -> $9.00 | View details for Leerink Partners rating of NeoGenomics (NASDAQ:NEO) on 4/30/2025 |
AKBA Akebia Therapeutics | $3.72
+1.1% | 4/28/2025 | Roanna Ruiz | Initiated Coverage | Outperform | $7.00 | View details for Leerink Partners rating of Akebia Therapeutics (NASDAQ:AKBA) on 4/28/2025 |
IRWD Ironwood Pharmaceuticals | $0.77
+1.0% | 4/14/2025 | Faisal Khurshid | Lower Price Target | Market Perform -> Market Perform | $3.00 -> $1.00 | View details for Leerink Partners rating of Ironwood Pharmaceuticals (NASDAQ:IRWD) on 4/14/2025 |
SYRE Spyre Therapeutics | $16.26
-4.2% | 4/8/2025 | Faisal Khurshid | Initiated Coverage | Outperform | $45.00 | View details for Leerink Partners rating of Spyre Therapeutics (NASDAQ:SYRE) on 4/8/2025 |
The $7 company helping Nvidia build the world’s first trillion-dollar robot … (Ad) Michael Robinson has been at the forefront of the technology market for over 40 years.
Spotting some profitable trends in tech … well ahead of Wall Street.
Like when he called Nvidia at a mere 80 cents a share.
Or Bitcoin when it was trading for just $300.
Throughout his illustrious career …
Michael has given his followers almost 150 different chances to register triple-digit gains. Now he's identified his next potential winner. Click here to find out more. |
CMPX Compass Therapeutics | $2.95
-0.7% | 4/2/2025 | Andrew Berens | Upgrade | Market Perform -> Outperform | $4.00 -> $6.00 | View details for Leerink Partners rating of Compass Therapeutics (NASDAQ:CMPX) on 4/2/2025 |
AIRS AirSculpt Technologies | $5.91
-10.6% | 3/31/2025 | Whit Mayo | Lower Price Target | Market Perform -> Market Perform | $6.50 -> $2.50 | View details for Leerink Partners rating of AirSculpt Technologies (NASDAQ:AIRS) on 3/31/2025 |
EQ Equillium | $0.71
+81.6% | 3/28/2025 | Thomas Smith | Reiterated Rating | Outperform -> Market Perform | $3.00 -> $1.00 | View details for Leerink Partners rating of Equillium (NASDAQ:EQ) on 3/28/2025 |
RGNX REGENXBIO | $8.19
-3.8% | 3/18/2025 | - | Set Price Target | | $24.00 | View details for Leerink Partners rating of REGENXBIO (NASDAQ:RGNX) on 3/18/2025 |
OPT Opthea | $3.41
| 3/25/2025 | Marc Goodman | Downgrade | Outperform -> Market Perform | $12.00 -> $1.00 | View details for Leerink Partners rating of Opthea (NASDAQ:OPT) on 3/25/2025 |
LXEO Lexeo Therapeutics | $4.61
-2.5% | 3/24/2025 | Mani Foroohar | Lower Price Target | Outperform -> Outperform | $19.00 -> $18.00 | View details for Leerink Partners rating of Lexeo Therapeutics (NASDAQ:LXEO) on 3/24/2025 |
MEDP Medpace | $423.09
-1.0% | 3/24/2025 | Michael Cherny | Initiated Coverage | Market Perform | $330.00 | View details for Leerink Partners rating of Medpace (NASDAQ:MEDP) on 3/24/2025 |
ELEV Elevation Oncology | $0.37
| 3/21/2025 | Andrew Berens | Downgrade | Outperform -> Market Perform | $9.00 -> $1.00 | View details for Leerink Partners rating of Elevation Oncology (NASDAQ:ELEV) on 3/21/2025 |
STTK Shattuck Labs | $0.73
-3.9% | 3/17/2025 | Faisal Khurshid | Initiated Coverage | Outperform | $4.00 | View details for Leerink Partners rating of Shattuck Labs (NASDAQ:STTK) on 3/17/2025 |
NRIX Nurix Therapeutics | $11.04
-2.0% | 3/17/2025 | Faisal Khurshid | Initiated Coverage | Market Perform | $16.00 | View details for Leerink Partners rating of Nurix Therapeutics (NASDAQ:NRIX) on 3/17/2025 |
TENX Tenax Therapeutics | $6.22
-0.3% | 3/10/2025 | - | Set Price Target | | $20.00 | View details for Leerink Partners rating of Tenax Therapeutics (NASDAQ:TENX) on 3/10/2025 |
XERS Xeris Biopharma | $5.38
+5.7% | 3/7/2025 | Roanna Ruiz | Boost Price Target | Outperform -> Outperform | $5.00 -> $6.00 | View details for Leerink Partners rating of Xeris Biopharma (NASDAQ:XERS) on 3/7/2025 |
CRMD CorMedix | $11.64
-0.3% | 3/7/2025 | Roanna Ruiz | Initiated Coverage | Outperform | $18.00 | View details for Leerink Partners rating of CorMedix (NASDAQ:CRMD) on 3/7/2025 |
LXRX Lexicon Pharmaceuticals | $1.07
| 3/4/2025 | Roanna Ruiz | Reiterated Rating | Outperform -> Market Perform | $2.00 -> $1.00 | View details for Leerink Partners rating of Lexicon Pharmaceuticals (NASDAQ:LXRX) on 3/4/2025 |
PLRX Pliant Therapeutics | $1.58
+8.2% | 3/3/2025 | Faisal Khurshid | Downgrade | Outperform -> Market Perform | $33.00 -> $2.00 | View details for Leerink Partners rating of Pliant Therapeutics (NASDAQ:PLRX) on 3/3/2025 |
RXRX Recursion Pharmaceuticals | $5.68
-4.5% | 2/28/2025 | Mani Foroohar | Lower Price Target | Market Perform -> Market Perform | $7.00 -> $6.00 | View details for Leerink Partners rating of Recursion Pharmaceuticals (NASDAQ:RXRX) on 2/28/2025 |
HIMS Hims & Hers Health | $62.57
-5.5% | 2/25/2025 | Michael Cherny | Boost Price Target | Market Perform -> Market Perform | $24.00 -> $40.00 | View details for Leerink Partners rating of Hims & Hers Health (NYSE:HIMS) on 2/25/2025 |
MAZE Maze Therapeutics | $14.90
+1.0% | 2/25/2025 | Joseph Schwartz | Initiated Coverage | Outperform | $28.00 | View details for Leerink Partners rating of Maze Therapeutics (NASDAQ:MAZE) on 2/25/2025 |
BBNX Beta Bionics | $16.40
-2.3% | 2/24/2025 | Mike Kratky | Initiated Coverage | Outperform | $28.00 | View details for Leerink Partners rating of Beta Bionics (NASDAQ:BBNX) on 2/24/2025 |
MGM MGM Resorts International | $35.75
-1.9% | 2/13/2025 | - | Downgrade | Market Perform | | View details for Leerink Partners rating of MGM Resorts International (NYSE:MGM) on 2/13/2025 |
LLY Eli Lilly and Company | $761.47
+2.9% | 1/17/2025 | Andrew Berens | Set Price Target | | $950.00 | View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 1/17/2025 |
ATYR aTyr Pharma | $4.70
-0.4% | 2/18/2025 | Faisal Khurshid | Initiated Coverage | Outperform | $16.00 | View details for Leerink Partners rating of aTyr Pharma (NASDAQ:ATYR) on 2/18/2025 |
TXG 10x Genomics | $13.08
-2.8% | 2/13/2025 | Mike Kratky | Downgrade | Outperform -> Market Perform | $25.00 -> $12.00 | View details for Leerink Partners rating of 10x Genomics (NASDAQ:TXG) on 2/13/2025 |
GMAB Genmab A/S | $21.78
+0.5% | 2/13/2025 | Jonathan Chang | Upgrade | Market Perform -> Outperform | $27.00 | View details for Leerink Partners rating of Genmab A/S (NASDAQ:GMAB) on 2/13/2025 |
CVS CVS Health | $62.52
+0.7% | 2/13/2025 | Michael Cherny | Upgrade | Market Perform -> Outperform | $55.00 -> $75.00 | View details for Leerink Partners rating of CVS Health (NYSE:CVS) on 2/13/2025 |
CVS CVS Health | $62.52
+0.7% | 2/11/2025 | - | Boost Price Target | Market Perform -> Market Perform | $51.00 -> $55.00 | View details for Leerink Partners rating of CVS Health (NYSE:CVS) on 2/11/2025 |
AXSM Axsome Therapeutics | $103.02
+1.6% | 2/10/2025 | Marc Goodman | Boost Price Target | Outperform -> Outperform | $110.00 -> $150.00 | View details for Leerink Partners rating of Axsome Therapeutics (NASDAQ:AXSM) on 2/10/2025 |
DOCS Doximity | $57.30
-2.5% | 2/7/2025 | Michael Cherny | Upgrade | Market Perform -> Outperform | $60.00 -> $90.00 | View details for Leerink Partners rating of Doximity (NASDAQ:DOCS) on 2/7/2025 |
HOLX Hologic | $67.16
+0.5% | 2/6/2025 | Puneet Souda | Downgrade | Outperform -> Market Perform | $80.00 -> $75.00 | View details for Leerink Partners rating of Hologic (NASDAQ:HOLX) on 2/6/2025 |
REGN Regeneron Pharmaceuticals | $558.87
+2.5% | 2/5/2025 | David Risinger | Upgrade | Market Perform -> Outperform | $762.00 -> $834.00 | View details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 2/5/2025 |
REGN Regeneron Pharmaceuticals | $558.87
+2.5% | 2/4/2025 | - | Lower Price Target | Market Perform -> Market Perform | $980.00 -> $862.00 | View details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 2/4/2025 |
ISRG Intuitive Surgical | $483.12
+0.4% | 1/27/2025 | - | Boost Price Target | | $490.00 -> $548.00 | View details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 1/27/2025 |
JNJ Johnson & Johnson | $167.33
+1.6% | 1/23/2025 | David Risinger | Lower Price Target | Outperform -> Outperform | $182.00 -> $169.00 | View details for Leerink Partners rating of Johnson & Johnson (NYSE:JNJ) on 1/23/2025 |
MRNA Moderna | $27.60
-6.6% | 1/16/2025 | - | Lower Price Target | Underweight -> Underweight | $31.00 -> $27.00 | View details for Leerink Partners rating of Moderna (NASDAQ:MRNA) on 1/16/2025 |
FDMT 4D Molecular Therapeutics | $6.42
+42.7% | 1/13/2025 | Mani Foroohar | Lower Price Target | Outperform -> Outperform | $31.00 -> $27.00 | View details for Leerink Partners rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 1/13/2025 |
SPRY ARS Pharmaceuticals | $17.18
-2.8% | 1/13/2025 | Roanna Ruiz | Boost Price Target | Outperform -> Outperform | $26.00 -> $27.00 | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 1/13/2025 |
VIR Vir Biotechnology | $5.03
-0.8% | 1/13/2025 | Roanna Ruiz | Boost Price Target | Outperform -> Outperform | $18.00 -> $20.00 | View details for Leerink Partners rating of Vir Biotechnology (NASDAQ:VIR) on 1/13/2025 |
MRK Merck & Co., Inc. | $79.27
+1.5% | 1/13/2025 | Daina Graybosch | Lower Price Target | Outperform -> Outperform | $136.00 -> $119.00 | View details for Leerink Partners rating of Merck & Co., Inc. (NYSE:MRK) on 1/13/2025 |
DGX Quest Diagnostics | $170.81
+2.0% | 1/6/2025 | - | Upgrade | Market Perform -> Outperform | $169.00 -> $174.00 | View details for Leerink Partners rating of Quest Diagnostics (NYSE:DGX) on 1/6/2025 |
ALGN Align Technology | $136.52
+5.8% | 1/6/2025 | - | Upgrade | Market Perform -> Outperform | $235.00 -> $280.00 | View details for Leerink Partners rating of Align Technology (NASDAQ:ALGN) on 1/6/2025 |
KYMR Kymera Therapeutics | $42.96
-1.8% | 12/27/2024 | - | Reiterated Rating | Outperform -> Outperform | $60.00 -> $60.00 | View details for Leerink Partners rating of Kymera Therapeutics (NASDAQ:KYMR) on 12/27/2024 |
LVTX LAVA Therapeutics | $1.42
-6.6% | 12/12/2024 | - | Reiterated Rating | Outperform -> Market Perform | $11.00 -> $2.00 | View details for Leerink Partners rating of LAVA Therapeutics (NASDAQ:LVTX) on 12/12/2024 |
QURE uniQure | $13.69
-1.7% | 12/11/2024 | - | Boost Price Target | Outperform -> Outperform | $26.00 -> $44.00 | View details for Leerink Partners rating of uniQure (NASDAQ:QURE) on 12/11/2024 |
QTTB Q32 Bio | $2.00
-9.9% | 12/11/2024 | - | Reiterated Rating | Outperform -> Market Perform | $68.00 -> $9.00 | View details for Leerink Partners rating of Q32 Bio (NASDAQ:QTTB) on 12/11/2024 |
ANIP ANI Pharmaceuticals | $63.93
+0.9% | 12/11/2024 | - | Initiated Coverage | Outperform | $80.00 | View details for Leerink Partners rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 12/11/2024 |
MYGN Myriad Genetics | $3.91
+1.8% | 12/9/2024 | - | Downgrade | Outperform -> Market Perform | $30.00 -> $21.00 | View details for Leerink Partners rating of Myriad Genetics (NASDAQ:MYGN) on 12/9/2024 |
OKUR OnKure Therapeutics | $2.20
-0.5% | 12/5/2024 | - | Initiated Coverage | Outperform | $33.00 | View details for Leerink Partners rating of OnKure Therapeutics (NASDAQ:OKUR) on 12/5/2024 |
RLMD Relmada Therapeutics | $0.59
-5.1% | 12/4/2024 | - | Reiterated Rating | Outperform -> Market Perform | $10.00 -> $1.00 | View details for Leerink Partners rating of Relmada Therapeutics (NASDAQ:RLMD) on 12/4/2024 |
RLAY Relay Therapeutics | $3.36
-4.5% | 12/4/2024 | - | Lower Price Target | Outperform -> Outperform | $19.00 -> $18.00 | View details for Leerink Partners rating of Relay Therapeutics (NASDAQ:RLAY) on 12/4/2024 |
JANX Janux Therapeutics | $23.56
-1.9% | 12/3/2024 | - | Boost Price Target | Outperform -> Outperform | $79.00 -> $91.00 | View details for Leerink Partners rating of Janux Therapeutics (NASDAQ:JANX) on 12/3/2024 |
The $7 company helping Nvidia build the world’s first trillion-dollar robot … (Ad) Michael Robinson has been at the forefront of the technology market for over 40 years.
Spotting some profitable trends in tech … well ahead of Wall Street.
Like when he called Nvidia at a mere 80 cents a share.
Or Bitcoin when it was trading for just $300.
Throughout his illustrious career …
Michael has given his followers almost 150 different chances to register triple-digit gains. Now he's identified his next potential winner. Click here to find out more. |
CLYM Climb Bio | $1.45
+3.6% | 12/2/2024 | - | Initiated Coverage | Outperform | $10.00 | View details for Leerink Partners rating of Climb Bio (NASDAQ:CLYM) on 12/2/2024 |
ZTS Zoetis | $147.40
+1.1% | 12/2/2024 | - | Initiated Coverage | Outperform | $215.00 | View details for Leerink Partners rating of Zoetis (NYSE:ZTS) on 12/2/2024 |
IDXX IDEXX Laboratories | $535.54
+0.2% | 12/2/2024 | - | Initiated Coverage | Outperform | $500.00 | View details for Leerink Partners rating of IDEXX Laboratories (NASDAQ:IDXX) on 12/2/2024 |
ELAN Elanco Animal Health | $13.80
+0.9% | 12/2/2024 | - | Initiated Coverage | Market Perform | $14.00 | View details for Leerink Partners rating of Elanco Animal Health (NYSE:ELAN) on 12/2/2024 |
AMGN Amgen | $296.88
+0.6% | 11/27/2024 | - | Lower Price Target | | $349.00 -> $302.00 | View details for Leerink Partners rating of Amgen (NASDAQ:AMGN) on 11/27/2024 |
JANX Janux Therapeutics | $23.56
-1.9% | 11/22/2024 | - | Initiated Coverage | Outperform | $79.00 | View details for Leerink Partners rating of Janux Therapeutics (NASDAQ:JANX) on 11/22/2024 |
ABBV AbbVie | $195.17
+3.3% | 11/22/2024 | - | Upgrade | Market Perform -> Outperform | $206.00 | View details for Leerink Partners rating of AbbVie (NYSE:ABBV) on 11/22/2024 |
IQV IQVIA | $182.44
-1.8% | 11/19/2024 | - | Reiterated Rating | Outperform -> Outperform | $260.00 -> $248.00 | View details for Leerink Partners rating of IQVIA (NYSE:IQV) on 11/19/2024 |
RCKT Rocket Pharmaceuticals | $2.99
-2.0% | 11/19/2024 | - | Lower Price Target | Outperform -> Outperform | $46.00 -> $44.00 | View details for Leerink Partners rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 11/19/2024 |
EHAB Enhabit | $6.53
-2.8% | 11/19/2024 | - | Reiterated Rating | Market Perform -> Market Perform | $8.50 -> $8.00 | View details for Leerink Partners rating of Enhabit (NYSE:EHAB) on 11/19/2024 |
ICLR Icon | $166.44
-1.6% | 11/19/2024 | - | Reiterated Rating | Outperform -> Outperform | $270.00 -> $255.00 | View details for Leerink Partners rating of Icon (NASDAQ:ICLR) on 11/19/2024 |
ACRS Aclaris Therapeutics | $1.53
| 11/19/2024 | - | Upgrade | Market Perform -> Outperform | $2.00 -> $7.00 | View details for Leerink Partners rating of Aclaris Therapeutics (NASDAQ:ACRS) on 11/19/2024 |
CMPX Compass Therapeutics | $2.95
-0.7% | 11/15/2024 | - | Downgrade | Outperform -> Market Perform | $5.00 -> $4.00 | View details for Leerink Partners rating of Compass Therapeutics (NASDAQ:CMPX) on 11/15/2024 |
LXEO Lexeo Therapeutics | $4.61
-2.5% | 11/13/2024 | - | Lower Price Target | Outperform -> Outperform | $20.00 -> $19.00 | View details for Leerink Partners rating of Lexeo Therapeutics (NASDAQ:LXEO) on 11/13/2024 |
MASS 908 Devices | $6.42
-2.0% | 11/13/2024 | - | Reiterated Rating | Outperform -> Market Perform | $12.00 -> $4.00 | View details for Leerink Partners rating of 908 Devices (NASDAQ:MASS) on 11/13/2024 |
ARDT Ardent Health | $10.21
-3.7% | 11/12/2024 | - | Boost Price Target | Outperform -> Outperform | $23.00 -> $25.00 | View details for Leerink Partners rating of Ardent Health (NYSE:ARDT) on 11/12/2024 |
NGNE Neurogene | $21.78
+0.0% | 11/12/2024 | - | Boost Price Target | Outperform -> Outperform | $45.00 -> $72.00 | View details for Leerink Partners rating of Neurogene (NASDAQ:NGNE) on 11/12/2024 |
BMY Bristol Myers Squibb | $44.25
+2.2% | 11/12/2024 | - | Upgrade | Market Perform -> Outperform | $55.00 -> $73.00 | View details for Leerink Partners rating of Bristol Myers Squibb (NYSE:BMY) on 11/12/2024 |
TECX Tectonic Therapeutic | $20.73
-6.6% | 11/11/2024 | - | Boost Price Target | Outperform -> Outperform | $49.00 -> $69.00 | View details for Leerink Partners rating of Tectonic Therapeutic (NASDAQ:TECX) on 11/11/2024 |
XRAY DENTSPLY SIRONA | $14.30
-0.1% | 11/7/2024 | - | Downgrade | Outperform -> Market Perform | | View details for Leerink Partners rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 11/7/2024 |
ZYME Zymeworks | $12.57
+0.1% | 11/7/2024 | - | Upgrade | Market Perform -> Outperform | $10.00 -> $25.00 | View details for Leerink Partners rating of Zymeworks (NYSE:ZYME) on 11/7/2024 |
BEAM Beam Therapeutics | $18.83
-4.5% | 11/6/2024 | - | Upgrade | Market Perform -> Outperform | $27.00 -> $39.00 | View details for Leerink Partners rating of Beam Therapeutics (NASDAQ:BEAM) on 11/6/2024 |
IDYA IDEAYA Biosciences | $24.27
-0.3% | 11/5/2024 | - | Downgrade | Outperform -> Market Perform | $41.00 -> $27.00 | View details for Leerink Partners rating of IDEAYA Biosciences (NASDAQ:IDYA) on 11/5/2024 |
ZURA Zura Bio | $1.50
+7.1% | 11/4/2024 | - | Initiated Coverage | Outperform | $15.00 | View details for Leerink Partners rating of Zura Bio (NASDAQ:ZURA) on 11/4/2024 |
NVST Envista | $20.78
+10.0% | 10/31/2024 | - | Upgrade | Underperform -> Market Perform | $16.00 -> $23.00 | View details for Leerink Partners rating of Envista (NYSE:NVST) on 10/31/2024 |
AQST Aquestive Therapeutics | $3.82
-0.5% | 10/25/2024 | - | Boost Price Target | Outperform -> Outperform | $12.00 -> $13.00 | View details for Leerink Partners rating of Aquestive Therapeutics (NASDAQ:AQST) on 10/25/2024 |
DXCM DexCom | $79.28
-1.8% | 10/25/2024 | - | Lower Price Target | Outperform -> Outperform | $90.00 -> $87.00 | View details for Leerink Partners rating of DexCom (NASDAQ:DXCM) on 10/25/2024 |
ICLR Icon | $166.44
-1.6% | 10/25/2024 | - | Lower Price Target | Outperform -> Outperform | $376.00 -> $270.00 | View details for Leerink Partners rating of Icon (NASDAQ:ICLR) on 10/25/2024 |
TENX Tenax Therapeutics | $6.22
-0.3% | 10/24/2024 | - | Initiated Coverage | Outperform | $16.00 | View details for Leerink Partners rating of Tenax Therapeutics (NASDAQ:TENX) on 10/24/2024 |
GILD Gilead Sciences | $113.18
+0.8% | 10/21/2024 | - | Upgrade | Market Perform -> Outperform | $74.00 -> $96.00 | View details for Leerink Partners rating of Gilead Sciences (NASDAQ:GILD) on 10/21/2024 |
TNYA Tenaya Therapeutics | $0.67
-0.8% | 10/18/2024 | - | Reiterated Rating | Outperform -> Outperform | | View details for Leerink Partners rating of Tenaya Therapeutics (NASDAQ:TNYA) on 10/18/2024 |
AMLX Amylyx Pharmaceuticals | $7.72
-3.9% | 10/18/2024 | Marc Goodman | Set Price Target | Market Perform -> Market Perform | $4.00 | View details for Leerink Partners rating of Amylyx Pharmaceuticals (NASDAQ:AMLX) on 10/18/2024 |
LXRX Lexicon Pharmaceuticals | $1.07
| 10/18/2024 | Roanna Ruiz | Set Price Target | Outperform -> Outperform | $6.00 | View details for Leerink Partners rating of Lexicon Pharmaceuticals (NASDAQ:LXRX) on 10/18/2024 |
ISRG Intuitive Surgical | $483.12
+0.4% | 10/17/2024 | - | Boost Price Target | | $489.00 -> $502.00 | View details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 10/17/2024 |
BBIO BridgeBio Pharma | $47.37
+0.2% | 10/17/2024 | - | Lower Price Target | Outperform -> Outperform | $47.00 -> $46.00 | View details for Leerink Partners rating of BridgeBio Pharma (NASDAQ:BBIO) on 10/17/2024 |
MIRM Mirum Pharmaceuticals | $52.02
+0.7% | 10/17/2024 | - | Boost Price Target | Outperform -> Outperform | $47.00 -> $49.00 | View details for Leerink Partners rating of Mirum Pharmaceuticals (NASDAQ:MIRM) on 10/17/2024 |
ILMN Illumina | $94.66
-7.8% | 10/17/2024 | - | Boost Price Target | Outperform -> Outperform | $160.00 -> $200.00 | View details for Leerink Partners rating of Illumina (NASDAQ:ILMN) on 10/17/2024 |
MASS 908 Devices | $6.42
-2.0% | 10/17/2024 | - | Lower Price Target | Outperform -> Outperform | $15.00 -> $12.00 | View details for Leerink Partners rating of 908 Devices (NASDAQ:MASS) on 10/17/2024 |
NTRA Natera | $134.58
+0.7% | 10/17/2024 | - | Boost Price Target | Outperform -> Outperform | $140.00 -> $150.00 | View details for Leerink Partners rating of Natera (NASDAQ:NTRA) on 10/17/2024 |
RVTY Revvity | $88.20
+0.3% | 10/17/2024 | - | Boost Price Target | Outperform -> Outperform | $130.00 -> $135.00 | View details for Leerink Partners rating of Revvity (NYSE:RVTY) on 10/17/2024 |
TWST Twist Bioscience | $33.68
+0.3% | 10/17/2024 | - | Boost Price Target | Market Perform -> Market Perform | $45.00 -> $48.00 | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 10/17/2024 |
VCYT Veracyte | $23.64
+0.6% | 10/17/2024 | - | Boost Price Target | Outperform -> Outperform | $35.00 -> $40.00 | View details for Leerink Partners rating of Veracyte (NASDAQ:VCYT) on 10/17/2024 |
GH Guardant Health | $41.42
+1.1% | 10/17/2024 | - | Lower Price Target | Outperform -> Outperform | $60.00 -> $50.00 | View details for Leerink Partners rating of Guardant Health (NASDAQ:GH) on 10/17/2024 |
WVE WAVE Life Sciences | $8.63
+6.5% | 10/16/2024 | - | Boost Price Target | Outperform -> Outperform | $20.00 -> $22.00 | View details for Leerink Partners rating of WAVE Life Sciences (NASDAQ:WVE) on 10/16/2024 |
VYGR Voyager Therapeutics | $2.96
-7.2% | 10/16/2024 | - | Initiated Coverage | Outperform | $15.00 | View details for Leerink Partners rating of Voyager Therapeutics (NASDAQ:VYGR) on 10/16/2024 |
MNMD Mind Medicine (MindMed) | $8.44
-7.2% | 10/14/2024 | - | Initiated Coverage | Outperform | $20.00 | View details for Leerink Partners rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 10/14/2024 |
STOK Stoke Therapeutics | $12.91
+0.5% | 10/14/2024 | - | Initiated Coverage | Outperform | $18.00 | View details for Leerink Partners rating of Stoke Therapeutics (NASDAQ:STOK) on 10/14/2024 |
HOLX Hologic | $67.16
+0.5% | 10/8/2024 | - | Lower Price Target | Outperform -> Outperform | $95.00 -> $90.00 | View details for Leerink Partners rating of Hologic (NASDAQ:HOLX) on 10/8/2024 |
TVTX Travere Therapeutics | $15.63
+1.2% | 10/8/2024 | - | Reiterated Rating | Outperform -> Outperform | $20.00 -> $20.00 | View details for Leerink Partners rating of Travere Therapeutics (NASDAQ:TVTX) on 10/8/2024 |
COR Cencora | $288.31
+0.8% | 10/7/2024 | - | Lower Price Target | Outperform -> Outperform | $277.00 -> $275.00 | View details for Leerink Partners rating of Cencora (NYSE:COR) on 10/7/2024 |
Microsoft's Next Big Bet? (Ad) Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-free energy. Bill Gates calls it “abundant” and is backing four separate startups in the space.
While most of these plays are off-limits to everyday investors, a little-known backdoor could give you access to one tiny company leading the charge—and it’s publicly traded. Get the name and ticker of this breakthrough energy stock before the window closes. |
MCK McKesson | $698.43
+0.7% | 10/7/2024 | - | Lower Price Target | Outperform -> Outperform | $665.00 -> $630.00 | View details for Leerink Partners rating of McKesson (NYSE:MCK) on 10/7/2024 |
HUM Humana | $247.19
-1.1% | 10/2/2024 | - | Downgrade | Outperform -> Market Perform | $400.00 -> $250.00 | View details for Leerink Partners rating of Humana (NYSE:HUM) on 10/2/2024 |
AQST Aquestive Therapeutics | $3.82
-0.5% | 9/30/2024 | - | Reiterated Rating | Outperform -> Outperform | $10.00 -> $12.00 | View details for Leerink Partners rating of Aquestive Therapeutics (NASDAQ:AQST) on 9/30/2024 |
AGIO Agios Pharmaceuticals | $35.00
-6.0% | 9/27/2024 | - | Downgrade | Outperform -> Market Perform | $60.00 -> $56.00 | View details for Leerink Partners rating of Agios Pharmaceuticals (NASDAQ:AGIO) on 9/27/2024 |
REGN Regeneron Pharmaceuticals | $558.87
+2.5% | 9/24/2024 | - | Reiterated Rating | Outperform -> Market Perform | $1,175.00 -> $1,077.00 | View details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 9/24/2024 |
BHVN Biohaven | $14.77
-2.2% | 9/23/2024 | - | Boost Price Target | Outperform -> Outperform | $55.00 -> $60.00 | View details for Leerink Partners rating of Biohaven (NYSE:BHVN) on 9/23/2024 |
SPRY ARS Pharmaceuticals | $17.18
-2.8% | 9/20/2024 | - | Boost Price Target | Outperform -> Outperform | $21.00 -> $25.00 | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/20/2024 |
APLT Applied Therapeutics | $0.44
-2.1% | 9/19/2024 | - | Boost Price Target | Outperform -> Outperform | $11.00 -> $14.00 | View details for Leerink Partners rating of Applied Therapeutics (NASDAQ:APLT) on 9/19/2024 |
FDMT 4D Molecular Therapeutics | $6.42
+42.7% | 9/19/2024 | - | Reiterated Rating | Outperform -> Outperform | $40.00 -> $36.00 | View details for Leerink Partners rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 9/19/2024 |
PGNY Progyny | $22.49
-4.3% | 9/19/2024 | - | Lower Price Target | Market Perform -> Market Perform | $25.00 -> $21.00 | View details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 9/19/2024 |
ICLR Icon | $166.44
-1.6% | 9/18/2024 | - | Initiated Coverage | Outperform | $379.00 | View details for Leerink Partners rating of Icon (NASDAQ:ICLR) on 9/18/2024 |
MRNA Moderna | $27.60
-6.6% | 9/17/2024 | - | Lower Price Target | Underperform -> Underperform | $60.00 -> $48.00 | View details for Leerink Partners rating of Moderna (NASDAQ:MRNA) on 9/17/2024 |
ORKA Oruka Therapeutics | $13.60
+0.1% | 9/17/2024 | - | Initiated Coverage | Outperform | $44.00 | View details for Leerink Partners rating of Oruka Therapeutics (NASDAQ:ORKA) on 9/17/2024 |
FULC Fulcrum Therapeutics | $6.83
+1.5% | 9/12/2024 | - | Reiterated Rating | Outperform -> Market Perform | $4.00 | View details for Leerink Partners rating of Fulcrum Therapeutics (NASDAQ:FULC) on 9/12/2024 |
INSP Inspire Medical Systems | $126.15
+1.3% | 9/10/2024 | - | Boost Price Target | Market Perform -> Market Perform | $167.00 -> $197.00 | View details for Leerink Partners rating of Inspire Medical Systems (NYSE:INSP) on 9/10/2024 |
MNKD MannKind | $3.75
-0.8% | 9/9/2024 | - | Initiated Coverage | Outperform | $7.00 -> $8.00 | View details for Leerink Partners rating of MannKind (NASDAQ:MNKD) on 9/9/2024 |
PLRX Pliant Therapeutics | $1.58
+8.2% | 9/9/2024 | - | Initiated Coverage | Outperform | $46.00 -> $33.00 | View details for Leerink Partners rating of Pliant Therapeutics (NASDAQ:PLRX) on 9/9/2024 |
PRTC PureTech Health | $19.09
+2.1% | 9/9/2024 | - | Initiated Coverage | Outperform | $58.00 -> $45.00 | View details for Leerink Partners rating of PureTech Health (NASDAQ:PRTC) on 9/9/2024 |
TRVI Trevi Therapeutics | $7.33
-1.1% | 9/9/2024 | - | Initiated Coverage | Outperform | $6.00 -> $7.00 | View details for Leerink Partners rating of Trevi Therapeutics (NASDAQ:TRVI) on 9/9/2024 |
IMUX Immunic | $0.93
-0.9% | 9/9/2024 | - | Reiterated Rating | Outperform | $5.00 | View details for Leerink Partners rating of Immunic (NASDAQ:IMUX) on 9/9/2024 |
KYMR Kymera Therapeutics | $42.96
-1.8% | 9/9/2024 | - | Reiterated Rating | Outperform | $60.00 | View details for Leerink Partners rating of Kymera Therapeutics (NASDAQ:KYMR) on 9/9/2024 |
IRWD Ironwood Pharmaceuticals | $0.77
+1.0% | 9/9/2024 | - | Initiated Coverage | Market Perform | $5.00 | View details for Leerink Partners rating of Ironwood Pharmaceuticals (NASDAQ:IRWD) on 9/9/2024 |
GERN Geron | $1.17
+1.7% | 9/9/2024 | - | Initiated Coverage | Outperform | $7.00 | View details for Leerink Partners rating of Geron (NASDAQ:GERN) on 9/9/2024 |
MCK McKesson | $698.43
+0.7% | 9/5/2024 | - | Lower Price Target | Outperform -> Outperform | $670.00 -> $665.00 | View details for Leerink Partners rating of McKesson (NYSE:MCK) on 9/5/2024 |
PCVX Vaxcyte | $33.02
-2.7% | 9/3/2024 | - | Boost Price Target | Outperform -> Outperform | $106.00 -> $153.00 | View details for Leerink Partners rating of Vaxcyte (NASDAQ:PCVX) on 9/3/2024 |
RXRX Recursion Pharmaceuticals | $5.68
-4.5% | 9/3/2024 | - | Lower Price Target | Market Perform -> Market Perform | $9.00 -> $8.00 | View details for Leerink Partners rating of Recursion Pharmaceuticals (NASDAQ:RXRX) on 9/3/2024 |
PEN Penumbra | $242.50
-3.9% | 9/3/2024 | - | Initiated Coverage | Outperform | $263.00 | View details for Leerink Partners rating of Penumbra (NYSE:PEN) on 9/3/2024 |
TXG 10x Genomics | $13.08
-2.8% | 9/3/2024 | - | Initiated Coverage | Outperform | $35.00 | View details for Leerink Partners rating of 10x Genomics (NASDAQ:TXG) on 9/3/2024 |
SPRY ARS Pharmaceuticals | $17.18
-2.8% | 8/12/2024 | - | Boost Price Target | Outperform | $19.00 -> $20.00 | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 8/12/2024 |
ARDT Ardent Health | $10.21
-3.7% | 8/12/2024 | - | Initiated Coverage | Outperform | $23.00 | View details for Leerink Partners rating of Ardent Health (NYSE:ARDT) on 8/12/2024 |
ARCT Arcturus Therapeutics | $12.30
+0.7% | 8/12/2024 | - | Initiated Coverage | Outperform | $70.00 | View details for Leerink Partners rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/12/2024 |
PGNY Progyny | $22.49
-4.3% | 8/7/2024 | - | Downgrade | Outperform -> Market Perform | $31.00 -> $25.00 | View details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 8/7/2024 |
TBPH Theravance Biopharma | $10.90
-2.3% | 8/6/2024 | - | Downgrade | Outperform -> Market Perform | $15.00 -> $10.00 | View details for Leerink Partners rating of Theravance Biopharma (NASDAQ:TBPH) on 8/6/2024 |
WAT Waters | $290.77
+0.7% | 8/1/2024 | - | Upgrade | Market Perform -> Outperform | $325.00 -> $375.00 | View details for Leerink Partners rating of Waters (NYSE:WAT) on 8/1/2024 |
TECX Tectonic Therapeutic | $20.73
-6.6% | 7/24/2024 | - | Initiated Coverage | Outperform | $49.00 | View details for Leerink Partners rating of Tectonic Therapeutic (NASDAQ:TECX) on 7/24/2024 |
DHR Danaher | $197.08
0.0% | 7/24/2024 | - | Boost Price Target | Outperform | $275.00 -> $280.00 | View details for Leerink Partners rating of Danaher (NYSE:DHR) on 7/24/2024 |
HCA HCA Healthcare | $356.84
+0.8% | 7/24/2024 | - | Boost Price Target | Outperform -> Outperform | $367.00 -> $396.00 | View details for Leerink Partners rating of HCA Healthcare (NYSE:HCA) on 7/24/2024 |
IONS Ionis Pharmaceuticals | $43.03
+0.1% | 7/24/2024 | - | Upgrade | Market Perform -> Outperform | $53.00 -> $62.00 | View details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 7/24/2024 |
ALMS Alumis | $4.13
-0.2% | 7/23/2024 | - | Initiated Coverage | Outperform | $29.00 | View details for Leerink Partners rating of Alumis (NASDAQ:ALMS) on 7/23/2024 |
CELC Celcuity | $39.91
+1.9% | 7/22/2024 | - | Initiated Coverage | Outperform | $29.00 | View details for Leerink Partners rating of Celcuity (NASDAQ:CELC) on 7/22/2024 |
BNTC Benitec Biopharma | $10.96
+0.3% | 7/22/2024 | - | Initiated Coverage | Outperform | $13.00 | View details for Leerink Partners rating of Benitec Biopharma (NASDAQ:BNTC) on 7/22/2024 |
LNTH Lantheus | $70.57
-0.9% | 7/11/2024 | - | Boost Price Target | Outperform -> Outperform | $106.00 -> $127.00 | View details for Leerink Partners rating of Lantheus (NASDAQ:LNTH) on 7/11/2024 |
EHC Encompass Health | $108.67
-1.3% | 7/10/2024 | - | Initiated Coverage | Outperform | $100.00 | View details for Leerink Partners rating of Encompass Health (NYSE:EHC) on 7/10/2024 |
HLVX HilleVax | $2.04
-3.3% | 7/9/2024 | - | Downgrade | Outperform -> Market Perform | $28.00 -> $2.00 | View details for Leerink Partners rating of HilleVax (NASDAQ:HLVX) on 7/9/2024 |
RVTY Revvity | $88.20
+0.3% | 7/8/2024 | - | Initiated Coverage | Outperform | $125.00 | View details for Leerink Partners rating of Revvity (NYSE:RVTY) on 7/8/2024 |
SDGR Schrodinger | $19.53
-3.9% | 7/2/2024 | - | Initiated Coverage | Outperform | $29.00 | View details for Leerink Partners rating of Schrodinger (NASDAQ:SDGR) on 7/2/2024 |
COR Cencora | $288.31
+0.8% | 6/27/2024 | - | Reiterated Rating | Outperform -> Outperform | $275.00 -> $275.00 | View details for Leerink Partners rating of Cencora (NYSE:COR) on 6/27/2024 |
ALNY Alnylam Pharmaceuticals | $401.80
+2.4% | 6/25/2024 | - | Boost Price Target | Market Perform -> Market Perform | $138.00 -> $159.00 | View details for Leerink Partners rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 6/25/2024 |
SLDB Solid Biosciences | $6.83
-0.1% | 6/24/2024 | - | Upgrade | Market Perform -> Outperform | $12.00 -> $12.00 | View details for Leerink Partners rating of Solid Biosciences (NASDAQ:SLDB) on 6/24/2024 |
SRPT Sarepta Therapeutics | $15.91
-3.1% | 6/24/2024 | - | Boost Price Target | Outperform -> Outperform | $165.00 -> $230.00 | View details for Leerink Partners rating of Sarepta Therapeutics (NASDAQ:SRPT) on 6/24/2024 |
Microsoft's Next Big Bet? (Ad) Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-free energy. Bill Gates calls it “abundant” and is backing four separate startups in the space.
While most of these plays are off-limits to everyday investors, a little-known backdoor could give you access to one tiny company leading the charge—and it’s publicly traded. Get the name and ticker of this breakthrough energy stock before the window closes. |
MREO Mereo BioPharma Group | $1.66
-1.8% | 6/20/2024 | - | Boost Price Target | Outperform -> Outperform | $6.00 -> $8.00 | View details for Leerink Partners rating of Mereo BioPharma Group (NASDAQ:MREO) on 6/20/2024 |
QTTB Q32 Bio | $2.00
-9.9% | 5/21/2024 | - | Initiated Coverage | Outperform | $54.00 | View details for Leerink Partners rating of Q32 Bio (NASDAQ:QTTB) on 5/21/2024 |
BOLT Bolt Biotherapeutics | $5.53
-2.1% | 5/15/2024 | - | Reiterated Rating | Outperform -> Market Perform | $60.00 -> $20.00 | View details for Leerink Partners rating of Bolt Biotherapeutics (NASDAQ:BOLT) on 5/15/2024 |
AIRS AirSculpt Technologies | $5.91
-10.6% | 5/14/2024 | - | Downgrade | Outperform -> Market Perform | $8.25 -> $5.00 | View details for Leerink Partners rating of AirSculpt Technologies (NASDAQ:AIRS) on 5/14/2024 |
EHAB Enhabit | $6.53
-2.8% | 5/14/2024 | - | Upgrade | Underperform -> Market Perform | $8.50 | View details for Leerink Partners rating of Enhabit (NYSE:EHAB) on 5/14/2024 |
AQST Aquestive Therapeutics | $3.82
-0.5% | 5/10/2024 | - | Initiated Coverage | Outperform | $8.00 | View details for Leerink Partners rating of Aquestive Therapeutics (NASDAQ:AQST) on 5/10/2024 |
MYGN Myriad Genetics | $3.91
+1.8% | 5/8/2024 | - | Upgrade | Market Perform -> Outperform | $25.00 -> $35.00 | View details for Leerink Partners rating of Myriad Genetics (NASDAQ:MYGN) on 5/8/2024 |
BPMC Blueprint Medicines | $129.46
| 5/6/2024 | - | Upgrade | Underperform -> Market Perform | $50.00 -> $97.00 | View details for Leerink Partners rating of Blueprint Medicines (NASDAQ:BPMC) on 5/6/2024 |
CVS CVS Health | $62.52
+0.7% | 5/1/2024 | - | Reiterated Rating | Outperform -> Market Perform | $87.00 -> $60.00 | View details for Leerink Partners rating of CVS Health (NYSE:CVS) on 5/1/2024 |
LXRX Lexicon Pharmaceuticals | $1.07
| 4/30/2024 | - | Initiated Coverage | Outperform | $5.00 | View details for Leerink Partners rating of Lexicon Pharmaceuticals (NASDAQ:LXRX) on 4/30/2024 |
XOMA XOMA Royalty | $24.77
-0.4% | 4/29/2024 | - | Initiated Coverage | Outperform | $40.00 | View details for Leerink Partners rating of XOMA Royalty (NASDAQ:XOMA) on 4/29/2024 |
NGNE Neurogene | $21.78
+0.0% | 4/29/2024 | - | Initiated Coverage | Outperform | $46.00 | View details for Leerink Partners rating of Neurogene (NASDAQ:NGNE) on 4/29/2024 |
IMCR Immunocore | $32.99
+0.7% | 4/29/2024 | - | Initiated Coverage | Outperform | $74.00 | View details for Leerink Partners rating of Immunocore (NASDAQ:IMCR) on 4/29/2024 |
CVAC CureVac | $5.41
+0.4% | 4/25/2024 | - | Downgrade | Outperform -> Market Perform | $12.00 -> $4.00 | View details for Leerink Partners rating of CureVac (NASDAQ:CVAC) on 4/25/2024 |
TNDM Tandem Diabetes Care | $15.40
-1.2% | 4/25/2024 | - | Upgrade | Market Perform -> Outperform | $34.00 -> $45.00 | View details for Leerink Partners rating of Tandem Diabetes Care (NASDAQ:TNDM) on 4/25/2024 |
RNAC Cartesian Therapeutics | $12.33
-3.7% | 4/23/2024 | - | Initiated Coverage | Outperform | $39.00 | View details for Leerink Partners rating of Cartesian Therapeutics (NASDAQ:RNAC) on 4/23/2024 |
ANAB AnaptysBio | $24.69
+0.6% | 4/16/2024 | - | Initiated Coverage | Outperform | $47.00 | View details for Leerink Partners rating of AnaptysBio (NASDAQ:ANAB) on 4/16/2024 |
MNMD Mind Medicine (MindMed) | $8.44
-7.2% | 4/15/2024 | - | Initiated Coverage | Outperform | $20.00 | View details for Leerink Partners rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 4/15/2024 |
LENZ LENZ Therapeutics | $29.96
+0.6% | 4/15/2024 | - | Initiated Coverage | Outperform | $32.00 | View details for Leerink Partners rating of LENZ Therapeutics (NASDAQ:LENZ) on 4/15/2024 |
ARDX Ardelyx | $4.33
+2.1% | 4/5/2024 | - | Initiated Coverage | Outperform | $14.00 | View details for Leerink Partners rating of Ardelyx (NASDAQ:ARDX) on 4/5/2024 |
LRMR Larimar Therapeutics | $3.44
-0.6% | 4/3/2024 | - | Initiated Coverage | Outperform | $25.00 | View details for Leerink Partners rating of Larimar Therapeutics (NASDAQ:LRMR) on 4/3/2024 |
NUVL Nuvalent | $77.76
-0.8% | 4/1/2024 | - | Upgrade | Market Perform -> Outperform | $69.00 -> $110.00 | View details for Leerink Partners rating of Nuvalent (NASDAQ:NUVL) on 4/1/2024 |
SGMT Sagimet Biosciences | $8.25
-5.1% | 3/25/2024 | - | Initiated Coverage | Outperform | $26.00 | View details for Leerink Partners rating of Sagimet Biosciences (NASDAQ:SGMT) on 3/25/2024 |
WBA Walgreens Boots Alliance | $11.64
| 3/18/2024 | - | Lower Price Target | Market Perform -> Market Perform | $23.00 -> $22.00 | View details for Leerink Partners rating of Walgreens Boots Alliance (NASDAQ:WBA) on 3/18/2024 |
MIRM Mirum Pharmaceuticals | $52.02
+0.7% | 3/18/2024 | - | Lower Price Target | Outperform -> Outperform | $44.00 -> $43.00 | View details for Leerink Partners rating of Mirum Pharmaceuticals (NASDAQ:MIRM) on 3/18/2024 |
AMLX Amylyx Pharmaceuticals | $7.72
-3.9% | 3/11/2024 | - | Downgrade | Outperform -> Market Perform | | View details for Leerink Partners rating of Amylyx Pharmaceuticals (NASDAQ:AMLX) on 3/11/2024 |
RGNX REGENXBIO | $8.19
-3.8% | 3/6/2024 | - | Upgrade | Market Perform -> Outperform | $37.00 | View details for Leerink Partners rating of REGENXBIO (NASDAQ:RGNX) on 3/6/2024 |
SPRY ARS Pharmaceuticals | $17.18
-2.8% | 3/5/2024 | - | Upgrade | Market Perform -> Outperform | $6.00 -> $18.00 | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 3/5/2024 |
KYTX Kyverna Therapeutics | $3.44
-3.6% | 3/4/2024 | - | Initiated Coverage | Outperform | $48.00 | View details for Leerink Partners rating of Kyverna Therapeutics (NASDAQ:KYTX) on 3/4/2024 |
WBA Walgreens Boots Alliance | $11.64
| 2/26/2024 | - | Initiated Coverage | Market Perform | $23.00 | View details for Leerink Partners rating of Walgreens Boots Alliance (NASDAQ:WBA) on 2/26/2024 |
XRAY DENTSPLY SIRONA | $14.30
-0.1% | 2/26/2024 | - | Initiated Coverage | Outperform | $42.00 | View details for Leerink Partners rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 2/26/2024 |
PGNY Progyny | $22.49
-4.3% | 2/26/2024 | - | Initiated Coverage | Outperform | $49.00 | View details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 2/26/2024 |
PINC Premier | $21.27
-1.0% | 2/26/2024 | - | Initiated Coverage | Market Perform | $22.50 | View details for Leerink Partners rating of Premier (NASDAQ:PINC) on 2/26/2024 |
OMI Owens & Minor | $6.61
-4.6% | 2/26/2024 | - | Initiated Coverage | Market Perform | $24.00 | View details for Leerink Partners rating of Owens & Minor (NYSE:OMI) on 2/26/2024 |
MCK McKesson | $698.43
+0.7% | 2/26/2024 | - | Initiated Coverage | Outperform | $600.00 | View details for Leerink Partners rating of McKesson (NYSE:MCK) on 2/26/2024 |
LH Labcorp | $261.34
+0.5% | 2/26/2024 | - | Initiated Coverage | Outperform | $260.00 | View details for Leerink Partners rating of Labcorp (NYSE:LH) on 2/26/2024 |
IQV IQVIA | $182.44
-1.8% | 2/26/2024 | - | Initiated Coverage | Outperform | $290.00 | View details for Leerink Partners rating of IQVIA (NYSE:IQV) on 2/26/2024 |
HIMS Hims & Hers Health | $62.57
-5.5% | 2/26/2024 | - | Initiated Coverage | Market Perform | $10.00 | View details for Leerink Partners rating of Hims & Hers Health (NYSE:HIMS) on 2/26/2024 |
GDRX GoodRx | $4.53
-5.4% | 2/26/2024 | - | Initiated Coverage | Outperform | $8.00 | View details for Leerink Partners rating of GoodRx (NASDAQ:GDRX) on 2/26/2024 |
NVST Envista | $20.78
+10.0% | 2/26/2024 | - | Initiated Coverage | Underperform | $19.00 | View details for Leerink Partners rating of Envista (NYSE:NVST) on 2/26/2024 |
TDOC Teladoc Health | $6.94
-3.7% | 2/26/2024 | - | Initiated Coverage | Market Perform | $17.00 | View details for Leerink Partners rating of Teladoc Health (NYSE:TDOC) on 2/26/2024 |
CVS CVS Health | $62.52
+0.7% | 2/26/2024 | - | Initiated Coverage | Outperform | $88.00 | View details for Leerink Partners rating of CVS Health (NYSE:CVS) on 2/26/2024 |
HSIC Henry Schein | $67.98
+0.5% | 2/26/2024 | - | Initiated Coverage | Market Perform | $78.00 | View details for Leerink Partners rating of Henry Schein (NASDAQ:HSIC) on 2/26/2024 |
DGX Quest Diagnostics | $170.81
+2.0% | 2/26/2024 | - | Initiated Coverage | Market Perform | $135.00 | View details for Leerink Partners rating of Quest Diagnostics (NYSE:DGX) on 2/26/2024 |
DOCS Doximity | $57.30
-2.5% | 2/26/2024 | - | Initiated Coverage | Market Perform | $32.00 | View details for Leerink Partners rating of Doximity (NASDAQ:DOCS) on 2/26/2024 |
CERT Certara | $9.54
-3.0% | 2/26/2024 | - | Initiated Coverage | Market Perform | $19.00 | View details for Leerink Partners rating of Certara (NASDAQ:CERT) on 2/26/2024 |
COR Cencora | $288.31
+0.8% | 2/26/2024 | - | Initiated Coverage | Outperform | $261.00 | View details for Leerink Partners rating of Cencora (NYSE:COR) on 2/26/2024 |
CAH Cardinal Health | $155.97
+0.5% | 2/26/2024 | - | Initiated Coverage | Outperform | $125.00 | View details for Leerink Partners rating of Cardinal Health (NYSE:CAH) on 2/26/2024 |
ALGN Align Technology | $136.52
+5.8% | 2/26/2024 | - | Initiated Coverage | Market Perform | $310.00 | View details for Leerink Partners rating of Align Technology (NASDAQ:ALGN) on 2/26/2024 |
APLT Applied Therapeutics | $0.44
-2.1% | 2/22/2024 | - | Initiated Coverage | Outperform | $12.00 | View details for Leerink Partners rating of Applied Therapeutics (NASDAQ:APLT) on 2/22/2024 |
RAPT Rapt Therapeutics | $10.49
-2.9% | 2/21/2024 | - | Downgrade | Outperform -> Market Perform | $336.00 -> $80.00 | View details for Leerink Partners rating of Rapt Therapeutics (NASDAQ:RAPT) on 2/21/2024 |
BTSG BrightSpring Health Services | $19.64
-4.9% | 2/20/2024 | - | Initiated Coverage | Outperform | $15.00 | View details for Leerink Partners rating of BrightSpring Health Services (NASDAQ:BTSG) on 2/20/2024 |
ENGN enGene | $3.83
+1.1% | 2/20/2024 | - | Initiated Coverage | Outperform | $31.00 | View details for Leerink Partners rating of enGene (NASDAQ:ENGN) on 2/20/2024 |
SYBX Synlogic | $1.48
-3.9% | 2/9/2024 | - | Reiterated Rating | Outperform -> Market Perform | | View details for Leerink Partners rating of Synlogic (NASDAQ:SYBX) on 2/9/2024 |
AMGN Amgen | $296.88
+0.6% | 2/7/2024 | - | Downgrade | Outperform -> Market Perform | $324.00 -> $318.00 | View details for Leerink Partners rating of Amgen (NASDAQ:AMGN) on 2/7/2024 |
UTHR United Therapeutics | $294.28
+7.1% | 2/5/2024 | - | Initiated Coverage | Outperform | $330.00 | View details for Leerink Partners rating of United Therapeutics (NASDAQ:UTHR) on 2/5/2024 |
NPCE NeuroPace | $8.99
+5.6% | 1/30/2024 | - | Initiated Coverage | Outperform | $22.00 | View details for Leerink Partners rating of NeuroPace (NASDAQ:NPCE) on 1/30/2024 |
IMNM Immunome | $10.59
+0.7% | 1/29/2024 | - | Initiated Coverage | Outperform | $30.00 | View details for Leerink Partners rating of Immunome (NASDAQ:IMNM) on 1/29/2024 |
PYXS Pyxis Oncology | $1.10
-1.8% | 1/23/2024 | - | Initiated Coverage | Outperform | $12.00 | View details for Leerink Partners rating of Pyxis Oncology (NASDAQ:PYXS) on 1/23/2024 |
AGL Agilon Health | $1.70
-5.3% | 1/8/2024 | - | Downgrade | Outperform -> Market Perform | | View details for Leerink Partners rating of Agilon Health (NYSE:AGL) on 1/8/2024 |
